Treating HIV in the developing world: getting ahead of the drug development curve

Drug Discovery Today

Volumn 12, Issue 1-2, 2007, Pages 1-3

  Ford, Nathan ^a   Calmy, Alexandra ^a,b   von Schoen Angerer, Tido ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIRETROVIRUS AGENT; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRASE INHIBITOR; LOPINAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOVIRUS 5; CHINA; DEVELOPING COUNTRY; DRUG COST; DRUG FORMULATION; DRUG INDUSTRY; DRUG RESEARCH; EDITORIAL; EUROPE; GOVERNMENT; GUATEMALA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; JAPAN; LAW SUIT; MONOTHERAPY; SOUTH AFRICA; THAILAND; TROPICS; TUBERCULOSIS; UNITED STATES;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; DRUG DESIGN; HIV INFECTIONS; HUMANS; PUBLIC OPINION;

EID: 33845907913     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.11.006     Document Type: Editorial

References (14)

1. Camp, R. et al. (2006) What's in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV and TB Therapies in Clinical Trials, Treatment Action, Group
2. Nolen, S. (2006) Drug access is critical, activists warn. Globe & Mail, 17 August
3. Altman, L. (2006) Talking about AIDS, with all the World watching. New York Times, 8 August
4. Anon. (2006) Untangling the web of Price Reductions: A Pricing Guide for the Purchase of ARVs for Developing Countries (9th edn), Médecins Sans Frontières (http://www.who.int/hiv/amds/price/en/index.html)
5. Mathiason, N. (2001) South Africa fights Aids drug apartheid. Observer, 14 January
6. McNeil, D. (2000) Selling cheap "generic" drugs, India's copycats irk industry. New York Times, 1 December
7. WHO (2006) Progress on Global Access to HIV Antiretoviral Therapy: A Report on "3 by 5" and Beyond, WHO (http://www.who.int/hiv/mediacentre/news57/en/index.html)
8. Ford N., and Darder M. Registration problems for antiretrovirals in Africa. Lancet 367 (2006) 794-795
9. IMS Health (2006) New Products and Markets Fuel Growth in 2005, IMS Health (http://www.imshealth.com/web/content/0,3148,64576068_63872702_70260998_ 77974518,00.html)
10. Ford, N. (2006) Compulsory licensing seen crucial for treatment. Bangkok Post, 17 August
11. Harwell J.I., et al. Antiretroviral therapy for children: substantial benefits but limited access. JAMA 296 (2006) 330-331
12. Trouille P., et al. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359 (2002) 2188-2194
13. Gerhardsen, T. (2006) Novartis persists with challenge to Indian Patent Law despite adversity. IP Watch, 19 October
14. Anon. (2006) Commission on Intellectual Property, Innovation and Public Health. Public health, innovation and intellectual property rights April; http://www.who.int/intellectualproperty/en